熱門資訊> 正文
MannKind的Afrezza正在接受FDA补充审查
2025-10-13 21:43
- MannKind Corporation (MNKD) announced that the U.S. FDA has accepted the supplemental marketing application seeking approval for Afrezza (insulin human) inhalation powder in children and adolescents living with type 1 or type 2 diabetes.
- The application has been assigned a target action date of May 29, 2026.
- The submission is based on results from the Phase 3 INHALE-1 study.
More on MannKind
- MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
- MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript
- MannKind rises as United Therapeutics exercises option for second inhalational drug
- MannKind to buy scPharmaceuticals to expand its cardiometabolic business
推薦文章
一周財經日曆 |下周重磅事件搶先看：美聯儲利率決議、科技巨頭財報密集來襲
美股機會日報 | 9月CPI低於預期！三大股指期貨直線拉昇；英特爾盤前大漲超5%
一周IPO | 八馬茶業、滴普科技預計下周二上市；傳賽力斯最快下周一招股
華盛早報 | 中美將於今起進行經貿磋商；盤后漲超7%！英特爾Q3營收增長2.8%
營收創新高、利潤暴跌29%！馬斯克的AI豪賭能撐起特斯拉的未來嗎？
財報前瞻 | iPhone17熱銷「帶飛」蘋果股價！大行績前集體齊聲看漲，Q4季報重點關注什麼？
甲骨文兩日跌超10%，「超預期宏偉目標」不再「吃香」？
小馬智行、文遠知行回港上市，迎Robotaxi 的deepseek時刻？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
